---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-001312"
form_type: "8-K"
ticker: "SBEV"
cik: "0001553788"
company_name: "SPLASH BEVERAGE GROUP, INC."
filed_at: "2026-10-05T20:02:20+00:00"
generated_at: "2026-10-12T14:49:11.772810+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Endovia's CannEpil for canine bone cancer pain gets FDA 'minor use' status, opening conditional approval path

## Summary
- FDA's Center for Veterinary Medicine determined CannEpil, an investigational CBD/THC oral solution for pain from bone cancer in dogs, qualifies as a 'minor use' under the MUMS program.
- The determination makes CannEpil eligible for the conditional approval pathway, and FDA said the minor-use status will be maintained through approval of the New Animal Drug Application (NADA).
- Endovia and Lupvindol BioSciences are scheduled to meet FDA on November 19, 2026 for a Pre-Submission Conference on required studies, manufacturing and regulatory submissions.
- The companies are finalizing U.S.-based FDA-compliant manufacturing to support a potential 2027 veterinary commercial launch; CannEpil remains an unapproved investigational new animal drug.

## SEC filing metadata
- accession: 0001731122-26-001312
- form_type: 8-K
- ticker: SBEV
- cik: 0001553788
- company_name: SPLASH BEVERAGE GROUP, INC.
- filed_at: 2026-10-05T20:02:20+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553788/000173112226001312/0001731122-26-001312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553788/000173112226001312/e7991_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-001312
- JSON: https://secwatch.observer/filing/0001731122-26-001312.json
- Plain text: https://secwatch.observer/filing/0001731122-26-001312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.